| Literature DB >> 25302690 |
Fahmida A Chowdhury1, Wessel Woldman2, Thomas H B FitzGerald3, Robert D C Elwes4, Lina Nashef4, John R Terry2, Mark P Richardson1.
Abstract
Idiopathic generalised epilepsy (IGE) has a genetic basis. The mechanism of seizure expression is not fully known, but is assumed to involve large-scale brain networks. We hypothesised that abnormal brain network properties would be detected using EEG in patients with IGE, and would be manifest as a familial endophenotype in their unaffected first-degree relatives. We studied 117 participants: 35 patients with IGE, 42 unaffected first-degree relatives, and 40 normal controls, using scalp EEG. Graph theory was used to describe brain network topology in five frequency bands for each subject. Frequency bands were chosen based on a published Spectral Factor Analysis study which demonstrated these bands to be optimally robust and independent. Groups were compared, using Bonferroni correction to account for nonindependent measures and multiple groups. Degree distribution variance was greater in patients and relatives than controls in the 6-9 Hz band (p = 0.0005, p = 0.0009 respectively). Mean degree was greater in patients than healthy controls in the 6-9 Hz band (p = 0.0064). Clustering coefficient was higher in patients and relatives than controls in the 6-9 Hz band (p = 0.0025, p = 0.0013). Characteristic path length did not differ between groups. No differences were found between patients and unaffected relatives. These findings suggest brain network topology differs between patients with IGE and normal controls, and that some of these network measures show similar deviations in patients and in unaffected relatives who do not have epilepsy. This suggests brain network topology may be an inherited endophenotype of IGE, present in unaffected relatives who do not have epilepsy, as well as in affected patients. We propose that abnormal brain network topology may be an endophenotype of IGE, though not in itself sufficient to cause epilepsy.Entities:
Mesh:
Year: 2014 PMID: 25302690 PMCID: PMC4193864 DOI: 10.1371/journal.pone.0110136
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Clinical characteristics of the patients.
| Gender | Age | Syndrome | Age of onset (years) | Seizures and frequency | Time since last seizure | Medications (total daily dose mg) | EEG | MRI |
| M | 26 | GTCS | 5 | GTCS 1/month | 2 weeks | Sodium Valproate 1600, Topiramate 200, Lamotrigine 100 | GSW | Normal |
| M | 25 | GTCS | 11 | GTCS 3/month | 3 weeks | Sodium Valproate 300 | GSW | Normal |
| F | 45 | GTCS | 2 | SF | 36 years | (none) | Normal | N/A |
| M | 31 | GTCS | 8 | GTCS 6/year | 1 month | Sodium Valproate 2000, Zonisamide 250, Levetiracetam 500, Lamotrigine 100 | GSW, Ph+ | N/A |
| F | 18 | JAE | 7 | GTCS 1/month, Abs SF | 1 week | Ethosuximide 250, Lamotrigine 600 | GSW | Normal |
| F | 20 | GTCS | 0.5 | SF | 9 years | (none) | Normal | N/A |
| M | 49 | GTCS | 26 | SF | 1 year | (none) | GSW | Normal |
| F | 21 | JAE | 10 | SF | 4 years | Lamotrigine 400, Ethosuximide 500 | GSW | Normal |
| F | 20 | JME | 13 | MJ weekly, GTCS SF | 1 week | Sodium Valproate 1000 | GSW | Normal |
| M | 59 | JME | 14 | SF | 10 years | (none) | GSW | N/A |
| F | 19 | GTCS | 15 | GTCS 4/year | 3 months | Levetiracetam 2000 | GSW | Normal |
| F | 28 | Unclassified | 20 | SF | 7 years | Carbamazepine 200 | Normal | Normal |
| F | 23 | CAE | 8 | SF | 6 years | Sodium Valproate 800, Lamotrigine 25 | GSW | Normal |
| M | 48 | JME | 17 | SF | 5 years | Sodium Valproate 1500, Topiramate 200, Carbamazepine 600 | GSW, PSW | N/A |
| F | 32 | CAE | 4 | GTCS SF, Abs weekly | 1 weeks | (none) | GSW | N/A |
| M | 30 | Unclassified | 11 | SF | 3 years | (none) | Normal | N/A |
| F | 28 | JME | 15 | SF | 13 years | Sodium Valproate 1400 | PSW | N/A |
| F | 41 | JME | 11 | GTCS rare, MJ weekly | 1 week | Levetiracetam 1000, Lamotrigine 500, Zonisamide 200 | GSW, PSW | N/A |
| M | 45 | CAE | 3 | SF | 2 years | Sodium Valproate 1400, Levetiracetam 2000 | GSW | N/A |
| M | 31 | Unclassified | 8 | SF | 10 years | Sodium Valproate 400 | Normal | Normal |
| M | 27 | Unclassified | 16 | SF | 10 years | Carbamazepine 1200 | Normal | N/A |
| F | 39 | GTCS | 22 | SF | 10 years | Carbamazepine 200 | GSW | Normal |
| M | 28 | CAE | 4 | SF | 5 years | Sodium Valproate 600, Levetiracetam 750, Lamotrigine 250 | GSW | N/A |
| F | 18 | JME | 15 | MJ SF, GTCS 1/month | 4 months | Levetiracetam 1000 | GSW | N/A |
| F | 36 | GTCS | 21 | GTCS 2/year | 2 months | Levetiracetam 1750 | GSW, Ph+ | Normal |
| F | 43 | CAE | 7 | SF | 10 years | (none) | GSW | N/A |
| M | 28 | GTCS | 8 | SF | 1 year | Sodium Valproate 400 | GSW | N/A |
| F | 53 | GTCS | 3 | GTCS SF, Abs daily | 1 day | (none) | GSW, Ph+ | Normal |
| F | 33 | JAE | 12 | GTCS 3/year | 4 months | Topiramate 400 | GSW, Ph+ | Normal |
| F | 55 | GTCS | 16 | SF | 25 years | (none) | Normal | N/A |
| M | 26 | CAE | 5 | SF | 8 years | (none) | GSW | N/A |
| F | 47 | JAE | 11 | Abs daily, GTCS SF | 1 day | Levetiracetam 2000 | PSW | Normal |
| M | 25 | JME | 14 | GTCS 5/year, MJ weekly | 1 week | Valproate | GSW | Normal |
| F | 20 | JME | 15 | MJ 2/month | 2 weeks | Lamotrigine 400, Levetiracetam 1500 | GSW | Normal |
| F | 21 | Absences with eyelid myoclonia | 6 | Abs daily, MJ weekly | 1 day | Lamotrigine 500 | PSW | N/A |
CAE childhood absence epilepsy, GTCS generalised tonic clonic seizures only, JAE juvenile absence epilepsy, JME juvenile myoclonic epilepsy, MJ myoclonic jerks, Abs absences, Ph + Photosensitivity; GSW generalised spike and wave, PSW polyspike and wave; SF Seizure Free; N/a not available.
Summary of effects found comparing three groups (normal controls, patients, relatives).
| Measure | Comparison | 1–5 Hz | 6–9 Hz | 10–11 Hz | 12–19 Hz | 21–70 Hz | |||||
| Uncorr. | Bonferroni corrected | Uncorr. | Bonferroni corrected | Uncorr. | Bonferroni corrected | Uncorr. | Bonferroni corrected | Uncorr. | Bonferroni corrected | ||
|
| difference between groups | 0.9513 | 0.0013 | 0.0064 | 0.9321 | 0.5501 | 0.5435 | ||||
|
| normals vs patients | 0.0003 | 0.0008 | ||||||||
|
| normals vs relatives | 0.0514 | |||||||||
|
| relatives vs patients | 0.0718 | |||||||||
|
| difference between groups | 0.8795 | 0.0001 | 0.0005 | 0.8533 | 0.6280 | 0.0441 | 0.2206. | |||
|
| normals vs patients | 0.0002 | 0.0005 | ||||||||
|
| normals vs relatives | 0.0003 | 0.0009 | ||||||||
|
| relatives vs patients | 0.5947 | |||||||||
|
| difference between groups | 0.9003 | 0.0004 | 0.0018 | 0.7291 | 0.5370 | 0.1315 | ||||
|
| normals vs patients | 0.0008 | 0.0025 | ||||||||
|
| normals vs relatives | 0.0004 | 0.0013 | ||||||||
|
| relatives vs patients | 0.8780 | |||||||||
|
| difference between groups | 0.5920 | 0.0814 | 0.4343 | 0.3798 | 0.8177 | |||||
|
| normals vs patients | ||||||||||
|
| normals vs relatives | ||||||||||
|
| relatives vs patients | ||||||||||
For details of Bonferroni correction see Methods. Uncorr = uncorrected.